Background: Definite diagnosis and therapeutic management of cholangiocarcinoma (CCA) remains a challenge. The aim of the current study was to investigate feasibility and potential impact on clinical management of targeted sequencing of intraductal biopsies.
Introduction
Cholangiocarcinoma (CCA) is a gastrointestinal neoplasia derived from the biliary epithelium or peribiliary glands 1 . The majority of CCA emerge from the extrahepatic bile ducts (eCCA) in the perihilar (50%) and distal (40%) region of the biliary tree whereas intrahepatic CCA (iCCA) occurs in <10% 2 . The current standard treatment in advanced stages consists of a systemic platinum-based chemotherapy and gemcitabine 3 . Many approaches of personalized therapy regimens have been evaluated, but so far, none could demonstrate a benefit in survival 4 . One reason might be a profound intertumoral heterogeneity requiring precise characterization of mutated targetable genes of every tumor 4 . Besides therapeutic management, definite diagnosis of CCA remains challenging, especially in patients with only small lesions in the extrahepatic biliary tract. These patients frequently present with indeterminate biliary stricture and obtaining a representative histopathological specimen is necessary to confirm diagnosis and avoid potentially unnecessary surgery. However, percutaneous puncture is often hindered due to the longitudinal growth of perihilar CCA and distal CCA, which also impedes reliable detection of the lesions in cross sectional imaging modalities. Therefore, the standard approach to obtain material for cytology or histopathology in non-operative cases or prior to surgery is by endoscopic retrograde cholangiography (ERC). Note that, due to the small size of specimens as well as the disconnected tissue structure and desmoplastic growth pattern of CCA, sensitivity of intraductal tissue brushings and intraductal biopsies remains below 50% 5 . Many approaches such as fluorescence in-situ hybridization or immunohistochemical techniques have been evaluated, but these are not widely established in diagnostic routine and sensitivity remains limited [6] [7] [8] [9] . Small size and poor tissue quality might be reasons, that to date, data on technical feasibility of nextgeneration sequencing of intraductal biopsies are lacking.
In the current study, suspicious biopsies of patients with indeterminate biliary stricture, who were diagnosed with CCA in further clinical course, were investigated with targeted sequencing. Therefore, we designed a customized panel of genes frequently mutated in CCA and used an enrichment technique specifically adapted to low input and low quality of DNA extracted from formalin-fixed, paraffin embedded (FFPE) tissue. The aim of the study was to investigate the feasibility of next-generation sequencing (NGS) from intraductal biopsies as a potential theranostic tool for both therapeutic management and diagnosis of CCA. Moreover, we aimed to further characterize the genetic landscape of biliary dysplasia.
Methods

Patients
Intraductal biopsies and matching surgical specimen collected from patients with a diagnosis of dysplasia or CCA between 2005 and 2015 at Frankfurt University Hospital were included in this study (n = 16). Samples with low or high-grade dysplasia as well as samples in which dysplasia could not be excluded were regarded as suspicious findings. If multiple biopsies were available, all were included. In total, 21 biopsies with either inconclusive findings (n = 3), biliary dysplasia (n = 15), or adenocarcinoma (n = 3) were included as well as corresponding surgical tumor specimens (n = 16), and benign control tissue (n = 16). If multiple biopsies were included, they were either obtained within the same intervention (P42, P43) or in two interventions within 3 months (P86b1-3 and P86b4). In two patients, tumor adjacent adenoma was microdissected from the FFPE sample of the surgical specimen and investigated as well (43d, 141d). Classification of iCCA, pCCA, and dCCA was based on pathological and clinical reports (if pathological reports were inconclusive) of the surgical specimens. All extrahepatic CCA involving the perihilar region were classified as pCCA, whereas all other extrahepatic CCA were classified as dCCA. The majority of CCA specimen was extrahepatic (distal: n = 9, perihilar: n = 3), whereas four cases were intrahepatic. Three cases with suspicion for carcinoma of the ampulla of Vater were included, since biliary etiology could not be excluded in these cases (P1, P139, P141). CCA were staged according to the 7th edition of the classification of the Union for International Cancer Control (UICC). Biomaterial and clinical data were obtained from the biobank and the tumor documentation of the UCT Frankfurt (University Cancer Center, Frankfurt, Germany). Informed consent was obtained from all patients. The study protocol was approved by the local ethics committee of the University of Frankfurt (Approval No. SGI-02-2015).
Intraductal biopsies were obtained during ERC with standard duodenoscopes under fluoroscopic guidance (Olympus V-Scopes, TJF 160VF, TJF-Q180 V; Olympus Europe, Hamburg, Germany). A large capacity forceps (Radial Jaw 4, M00513320, 2.8 mm diameter working channel, Boston Scientific, Marlborough, MA) as well as forceps with lower diameter (EndoJaw FB-231K, 1.9 mm, Olympus; EndoBite BIO1-C4-18-260, 1.8 mm, Medwork, Hochstadt/Aisch, Germany) were used.
Sample preparation
Hematoxylin and eosin (H&E) stained slides were reviewed by an expert gastrointestinal pathologist and representative FFPE blocks of biopsy, tumor and nontumor tissue were selected. Non-infiltrated tissue of liver or small intestine served as non-tumor tissue. H&E stained slides were examined by an expert gastrointestinal pathologist to determine the content of neoplastic or dysplastic cells. Biopsy samples were reviewed and classified according to grade of biliary intraepithelial neoplasia (BilIN 10, 11 ). Before DNA purification, size of the biopsies was measured on the FFPE block and all biopsies with a diameter ≤ 1 mm (n = 6) were assessed as 0. 5 Figure S1 .
Custom panel design
A CCA-specific sequencing panel was created based on recurrently mutated genes in large scale or targeted sequencing projects on iCCA (all genes reported to be mutated in ≥two independent publications [12] [13] [14] [15] [16] [17] [18] [19] [20] as well as genes already described to be mutated in ≥3% of biliary tract cancer in the COSMIC database (data extracted May 2016) 21 . The following genes were completely covered: ARID1A, ARID2, AXIN1, BAP1, BRAF, BRCA1, CDH1, CDKN2A, CTNNB1, ELF3, EPHA2, ERBB2, ERBB3, FAM47A, FBXW7, FGFR2, FGFR3, GNAS, IDH1, IDH2, KRAS, MDM2, MET, MUC4, NRAS, PBRM1, PIK3CA, PTEN, RNF43, ROBO2, SMAD4, SMARCA4, STK11, TERT, and TP53. For the following large genes, only functional relevant domains and known mutagenic positions were selected: ADAMTSL3, APC, ATM, FAT1, MUC16, and NF1. The potential tumor suppressor gene CSMD1 was not included in the panel due to large size and missing data on cancer relevant domains, although described to be mutated in CCA. Based on the mutation frequency of the Cosmic database entry for biliary tract cancer (data extracted 05/2016), an estimated mutation frequency of 2.1 mutations per tumor sample was calculated for our cohort of 16 patients (Supplementary  Table S1 ). Amplicon size of the designed panel was 175 base pairs (bp) and the final panel had a size of 1588 amplicons with a total length of 223,083 bp. Chromosomal positions of the panel design are provided in Supplementary Table S2 .
Sequencing and variant calling
Detailed information on enrichment and variant calling pipeline is provided in the supplementary information. Briefly, an enrichment method targeting both DNA strands was used and library preparation was performed with TruSeq Custom Amplicon Low Input Panel (Illumina, San Diego, CA) according to the manufacturer's instructions. For sequencing, an Illumina NextSeq500 (150 bp paired-end runs) with two High Output cartridges v2 (300 cycles) was used. Variants were first called separately for each probe set and only variants present in both probe sets with a cumulative depth of 1000× or average depth of 500× per probe set were called. Only non-synonymous variants in exons or splice sites of the targeted genes with a variant allele frequency of ≥5% (mean of both probe sets) were further analyzed. All mutations with suspicion for sequencing or alignment error in manual review were removed. Sanger or pyrosequencing were used for validation, as appropriate. Primer sequences are listed in Supplementary Table S3 .
Statistics
Data were collected and analyzed by BiAS (version 11.01, BiAS for Windows; Epsilon-Verlag, Frankfurt, Germany). Descriptive statistics, such as calculation of mean value, range, and standard deviation (SD) were determined using BiAS as well. Box-plot diagrams for supplemental Figure S2 included quartiles and were generated based on mean and SD. Survival was calculated as time from date of surgery to death or date of last contact. Uniformity was defined as % of reads with >0.2× mean coverage.
Results
Patients
Mean age at surgery was 68 years (range 48-82, SD 9.6) and 11/16 (69%) patients were male. Mean time between date of obtaining the intraductal biopsy and surgery was 30 days (range 8-84, SD 21.9). P86 had a biliary papillomatosis and P140 a biliary cystadenoma as precancerous lesions. All other patients had no underlying diseases in the biliary tract or the liver. 13/16 patients had already died at the time of study closure and mean survival was 9.6 mo (range 0-28 mo, SD 7.6). One patient is still alive (P51), while for two patients (P36, P139) no follow up was available. 7/16 tumors had stage III or IV. Data on CA19-9 level prior to surgery were available only for 8/16 patients and were elevated in four of these eight patients. Clinicopathological characteristics are shown in Table 1 .
Sequencing performance
One aim of the study was to evaluate technical feasibility of NGS from intraductal FFPE biopsies in our cohort of 16 patients. Mean diameter of included intraductal biopsies was 2.2 mm (range 0.5-8 mm). Estimated mean content of neoplastic or dysplastic cells was 45% (range 20-80%) for surgical resected tumor samples and 57% (10-90%) for intraductal biopsies. Sufficient DNA for library preparation (>10 ng) could be purified in all cases. Mean amplicon coverage of all samples was 6603× (range 3269-11,670×, SD 1772) and a mean uniformity of 92.5% (range 79.3-94.6, SD 2.7) was yielded. Mean amplicon coverage and uniformity of biopsies (6523×, 91.5%, SD 1752), tumor (6988×, 93.1%, SD 1543), and control samples (6231×, 92.7%, SD 2015) were comparable. Notably, mean coverage of very small biopsies (<1 mm, n = 6: 6205×, range 5328-8923, SD 1364) was only slightly lower compared to the rest of biopsies (6650×, range 4140-11,670, SD 1913) and mean uniformity was equal (91.5% vs 91.7%). Representative SNVs (n = 5) and Indels (n = 7) were successfully validated with Sanger or pyrosequencing (validation rate 100%). An overview of sequencing performance of biopsies is provided in Table 2 . A comparison of sequencing performance of biopsies and surgical specimen is given in Supplementary  Figure S2 and full sequencing data is shown in Supplementary Table S4 as well.
Molecular analysis
In total, 79 mutations in 44 positions of 20 genes in all dysplastic and neoplastic samples (n = 39) were identified. A mean of 1.7 mutations per surgical specimen (range 0-4) and 2.3 (range 0-6) per biopsy specimen was detected. The majority of the detected mutations were missense (49/79, 62%) and frameshift variants (17/79, 22%). Mean allele frequency was higher in surgical tumor specimens (27%, range 4.66-53.8%) compared to biopsy samples (17.7%, range 4.8-79.9%). C > T/G > A (52% of SNVs) and T > C/A > G (19.3%) transitions were found more frequently than C > A/G > T (18%) and T > G/A > C (12%) transversions. Interestingly, no C > G/G > C and T > A/A > T transversions were observed. An overview of mutational characteristics is provided in Fig. 1 .
Some genes were found to be recurrently mutated. Mutations of ARID1A, ARID2, BAP1, EPHA2, ERBB3, GNAS, MET, NF1, PBRM1, PIK3CA,and RNF43 were found in two different patients, while SMAD4 was found to be mutated in four and TP53 in five patients, respectively. One position was mutated in two cases (17:7578263 of TP53 in P36 and P86).
In two patients, no mutations were found in both biopsy and tumor specimen (P6, P8). All identified mutations are provided in Supplementary Table S5 .
Mutational load of biopsies in relation to degree of dysplasia and sample size Another aim of this study was to analyze mutational profiles of biliary dysplasia and intraductal samples with BilIN 1 (n = 5), BilIN 2 (n = 7), and BilIN 3 (n = 6) and tumor adjacent dysplasia (n = 2). Notably, in three cases it was not possible to conclusively differentiate between a BilIN and reactive changes by means of histopathology due to inflammation. The mean mutational load was 2.7 for BilIN 1 (range 2-3), 2 for BilIN 2 (0-5), and 2.8 for -5) . Overall, at least one mutation was detected in 14/18 (78%) biopsies with dysplasia or inconclusive findings. Of note, in one sample with inconclusive histological findings three mutations were found as well. In very small biopsies (≤1 mm), a mean of 1.2 (2-3) mutations was found compared to 2.7 mutations (0-6) in the larger biopsies (mean diameter 2.9 mm). Data on dysplasia grade including amount of detected mutations is provided in Table 2 . A representative case with indeterminate biliary stricture including endoscopic and histopathological evaluation is shown in Fig. 2 . Furthermore, we wanted to determine a potential correlation of the most frequently mutated genes (TP53, SMAD4) with the degree of dysplasia. Of note, apart from one specimen with BilIN 2 (P86b1), all samples with TP53 mutations were either BilIN3 or CCA. Mutations in SMAD4 were found in CCA samples as well as BilIN 1 (43b1, 1b, 1t) and BilIN 2 (42b2). Collectively, in 7/15 cases (47%) with dysplastic biopsies either SMAD4 or TP53 were found to be mutated.
Genetic heterogeneity
We further aimed to investigate a potential presence of subclonality within biliary dysplasia and neoplasia. The majority of variants was detected in both biopsy and corresponding tumor tissue (54/79, 68%). Notably, 22 mutations (28%) were found only in the biopsy samples while three mutations (4%) were found in the tumor sample but not in the biopsy. Two of these mutations were found in a patient with a very small biopsy (<0.5 mm, P67) with a comparably low (40%) content of dysplastic cells. In cases with multiple biopsies obtained, different mutations were identified such as in P86 where three mutations were found in one biopsy (b1) compared to five mutations in the other biopsies (b2, b3, and b4). Moreover, in another patient (P43b1), three mutations were found in the biopsy but none in the tumor sample. There was no difference of detected mutations in the two samples of tumor adjacent adenoma and the corresponding tumor sample. Figure 3 gives an overview of mutated genes of all samples of this study.
Potential driver mutations and therapeutical relevance
Of the 44 identified mutated positions, 32 were classified as likely pathogenic mutations since they had a SIFT score of ≤0.05, or were nonsense or frameshift mutations 22 . The other twelve mutations were assessed as variants of uncertain significance. Interestingly, all three mutations detected in the biopsy of Patient 1, which was inconclusive in histopathological examination, were likely pathogenic mutations (Fig. 2) . The 22 mutations detected only in the biopsy but not in the tumor included both likely pathogenic mutations (n = 14) and variants of uncertain significance (n = 8).
To investigate a potential theranostic value of targeted sequencing of intraductal biopsies, genes known as potentially relevant in targeted cancer therapy were assessed as well. In 6/16 patients (37.5%), mutations in therapeutically relevant genes were identified and likely pathogenic mutations were found in EPHA2, ERBB3, PIK3CA, and PTEN. Mutations of therapeutically relevant genes are shown in Table 3 .
Discussion
In the present study we analyzed FFPE specimens of patients with biliary dysplasia in the intraductal biopsy and CCA in further clinical course by applying a targeted, CCA-specific dual strand NGS-based analysis. Thereby, 1.8 non-synonymous mutations per tumor and 2.3 nonsynonymous mutations per biopsy were identified. This is consistent with an estimated amount of 2.1 mutations per Diameter of intraductal biopsies as well as estimated tumor content (based on hematoxylin-eosin stained sections, HE) and corresponding detected mutations and sequencing data. All biopsies with a diameter <1 mm were assessed as 0.5 mm n.e. not evaluable tumor sample, which was calculated based on the mutation frequency in biliary tract cancer of the Cosmic database (Supplementary Table S1 ) 21 . Library preparation as well as sequencing was successful in all samples and no difference in sequencing performance in relation to biopsy size was observed. Notably, a lower number of variants was observed in very small biopsies (<0.5 mm) compared to the larger ones potentially indicating that sensitivity of NGS from these biopsies might be decreased. Even so, these data demonstrate that the dual strand approach can be regarded as a suitable method to perform targeted sequencing of very small FFPE biopsies. Notably, NGS from low FFPE tissue amounts such as bronchial biopsies was reported, but these are the first data of NGS from the considerably smaller intraductal biopsies 23 . Besides technical feasibility, our results revealed a substantial genetic heterogeneity of biliary dysplasia and neoplasia in the investigated gene set, as 28% of mutations were only found in biopsy samples but not in the corresponding surgical specimen. Furthermore, a slightly higher mutation rate was found in biopsy samples compared to tumor samples while allele frequency was lower. These data show that biliary dysplasia contain a marked subclonality and indicate that CCA might derive from a minority subclone of dysplasia. This is exemplified in intraductal biopsy 86b3 which was diagnosed as dysplasia as well as invasive CCA: this sample shares mutations with the resected tumor as well as with other biopsies of the patient with only biliary dysplasia. These findings are in line with recent reports on mutational landscape of Barrett's esophagus and esophageal adenocarcinoma as well as oral precancerous lesions where a profound subclonal heterogeneity was shown 24, 25 . On the other hand, a study on pre-invasive stages of esophageal carcinogenesis reported that the majority of recurrently mutated genes were found in both metaplastic never-dysplastic Barrett's esophagus and esophageal adenocarcinoma, but TP53 and SMAD4 were confined to high-grade dysplasia and carcinoma indicating that these mutations represent major tumor drivers in this entity 26 . This corresponds to our findings, where TP53 and SMAD4 were found being mutated in 47% of dysplastic biopsies. TP53 was mutated only in BilIN 3 and CCA in contrast to SMAD4, which was found to be mutated in BilIN 1 and 2 as well as CCA, indicating the need of further characterization of SMAD4 mutations in non-CCA associated biliary dysplasia. In particular, while a recent study of our group revealed a small amount of intratumoral heterogeneity in iCCA, these are the first data on genetic heterogeneity of biliary dysplasia 27 . Further studies are warranted including more samples and more patients to determine presence of different mutated cancer pathways in pre-invasive and invasive disease. These observations have to be kept in mind when including patients to targeted therapy trials based on mutations from a single biopsy.
Added to the revealed genetic heterogeneity, our results indicate that NGS might be a potentially promising tool to enhance the diagnostic yield of intraductal biopsies in patients with indeterminate biliary stricture. For example, likely pathogenic mutations were observed in a tissue sample with inconclusive histopathological findings (P1) and the majority of BilINs was found to harbor mutations within the CCA-specific gene panel. Moreover, the correlation of TP53 with BilIN 3 and CCA indicates that sequencing of TP53 in intraductal biopsies helps to strengthen a suspicion for malignancy in inconclusive cases. Although TP53 is the most frequently mutated gene in CCA, mutation rate is still below 40% (Supplementary Table S1) demonstrating that sequencing of a larger gene panel such as used in the current study might increase the diagnostic value. These data point to a potential impact of NGS on future clinical management of patients with indeterminate biliary stricture by strengthening or weakening suspicion for a malignancy: The additional information might be essential for patients with CCA, since in these cases surgery should be performed as soon as possible to improve chances for a curative resection. On the other hand it might help to avoid surgery in non-malignant etiologies of biliary stricture which was reported in up to 17% 28, 29 . Final diagnosis after surgery in cases with a benign CCA-mimicking etiology were mostly inflammatory strictures which are unlikely to harbor CCA associated mutations. However, prospective validation studies with larger cohorts including dysplastic lesions without development of invasive disease are needed to adequately assess the diagnostic yield of NGS. It has to be considered that NGS is still a very costly method, and in the present study a highly adapted approach with a dual strand enrichment technique and a customized CCA-specific panel was used. Even so, implementation of cancer gene panels in routine diagnostics has already begun, areas of clinical application are increasing and costs are decreasing. Apart from a potential diagnostic value, our data indicate that NGS of intraductal biopsies might serve as a potential screening tool for personalized therapy regimens. Mutations were identified in potentially therapeutically relevant genes such as EPHA2, FGFR3, ERBB3, MET, PIK3CA, and PTEN. This highlights that NGS of intraductal biopsies might help to assign patients to targeted therapy trials according to the mutated cancer pathway. For example, trials including patients with CCA and FGFR alterations are currently ongoing (NCT01752920, NCT02150967). Moreover, the mutational profile can be assessed in further clinical course in case of disease progression or recurrent disease to detect potential additional driver mutations or mutations in genes associated with resistance to personalized therapy. In addition, obtaining intraductal biopsies is a safe method rarely causing complications and since most patients need recurrent ERC for stent placement, it reduces additional effort and risk (e.g., in comparison to transcutaneous biopsy) for the patient 30 . However, due to the genetic heterogeneity, results from a single biopsy should always be interpreted with caution. Moreover, as it is recommended for histopathological analysis to obtain multiple biopsies, NGS should also be performed based on DNA isolated from multiple biopsies to reduce the bias of genetic heterogeneity 30 . Some limitations must be considered to interpret data of our study. First of all, all dysplasias analyzed were most likely directly tumor adjacent and NGS data on BilIN without appearance of CCA such as in a chronological study are still lacking. Moreover, no patient with primary sclerosing cholangitis was included-a well-known risk factor for CCA with frequent occurrence of BilIN 31 . Secondly, we included tumors from different areas of the biliary tract (iCCA, pCCA, dCCA, ampullary carcinoma) as well as a varying number of dysplastic samples per patient resulting in a heterogeneous study cohort. Thirdly, genetic heterogeneity is most likely far more complex than revealed by our panel-sequencing approach and highly comprehensive data on eCCA are still due.
In conclusion, the present study demonstrates that NGS of intraductal biopsies is technically feasible and potentially improves the diagnostic yield in indeterminate biliary stricture and CCA. Moreover, a substantial genomic heterogeneity in biliary dysplasia and neoplasia was revealed, which needs to be considered in therapeutic management of patients with CCA and targeted therapy trials.
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